{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:56:06Z","timestamp":1791158166939,"version":"4.1.0"},"reference-count":26,"publisher":"American Association for Cancer Research (AACR)","issue":"7","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Inhibition of the survival kinase Akt can trigger apoptosis, and also has been found to activate autophagy, which may confound tumor attack. In this study, we investigated regulatory mechanisms through which apoptosis and autophagy were modulated in tumor cells subjected to Akt inhibition by MK-2206, the first allosteric small molecule inhibitor of Akt to enter clinical development. In human glioma cells, Akt inhibition by MK-2206 or siRNA-mediated attenuation strongly activated autophagy, whereas silencing of eukaryotic elongation factor-2 (eEF-2) kinase, a protein synthesis regulator, blunted this autophagic response. Suppression of MK-2206\u2013induced autophagy by eEF-2 silencing was accompanied by a promotion of apoptotic cell death. Similarly, siRNA-mediated inhibition of eEF-2 kinase potentiated the efficacy of MK-2206 against glioma cells. Together, these results showed that blunting autophagy and augmenting apoptosis by inhibition of eEF-2 kinase could modulate the sensitivity of glioma cells to Akt inhibition. Our findings suggest that targeting eEF-2 kinase may reinforce the antitumor efficacy of Akt inhibitors such as MK-2206. Cancer Res; 71(7); 2654\u201363. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-2889","type":"journal-article","created":{"date-parts":[[2011,2,9]],"date-time":"2011-02-09T21:11:31Z","timestamp":1297285891000},"page":"2654-2663","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":128,"title":["eEF-2 Kinase Dictates Cross-Talk between Autophagy and Apoptosis Induced by Akt Inhibition, Thereby Modulating Cytotoxicity of Novel Akt Inhibitor MK-2206"],"prefix":"10.1158","volume":"71","author":[{"given":"Yan","family":"Cheng","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingcong","family":"Ren","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"},{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Patel","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati","family":"Sharma","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Robertson","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Yan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rubin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Ming","family":"Yang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Pharmacology and The Penn State Hershey Cancer Institute, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; 2Department of Pharmacology, School of Medicine, Soochow University, Jiangsu Province, China; 3Department of Pathology, Robert Wood Johnson Medical School\u2014University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey; and 4Merck & Co. Inc., North Wales, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,3,31]]},"reference":[{"key":"2022061702445726300_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2003.11.009","article-title":"Structure, regulation and function of PKB\/AKT\u2013a major therapeutic target","volume":"1697","author":"Hanada","year":"2004","journal-title":"Biochim Biophys Acta"},{"key":"2022061702445726300_bib2","doi-asserted-by":"crossref","first-page":"7455","DOI":"10.1038\/sj.onc.1209085","article-title":"Perturbations of the AKT signaling pathway in human cancer","volume":"24","author":"Altomare","year":"2005","journal-title":"Oncogene"},{"key":"2022061702445726300_bib3","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"2022061702445726300_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.200801099","article-title":"Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents","volume":"183","author":"Degtyarev","year":"2008","journal-title":"J Cell Biol"},{"key":"2022061702445726300_bib5","first-page":"753","article-title":"Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy","volume":"31","author":"Fujiwara","year":"2007","journal-title":"Int J Oncol"},{"issue":"Suppl 2","key":"2022061702445726300_bib6","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/sj.cdd.4401780","article-title":"Macroautophagy versus mitochondrial autophagy: a question of fate?","volume":"12","author":"Kundu","year":"2005","journal-title":"Cell Death Differ"},{"issue":"Suppl 2","key":"2022061702445726300_bib7","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/sj.cdd.4401721","article-title":"Doctor Jekyll and Mister Hyde: autophagy can promote both cell survival and cell death","volume":"12","author":"Eskelinen","year":"2005","journal-title":"Cell Death Differ"},{"key":"2022061702445726300_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/334170a0","article-title":"Phosphorylation of elongation factor 2 by EF-2 kinase affects rate of translation","volume":"334","author":"Ryazanov","year":"1988","journal-title":"Nature"},{"key":"2022061702445726300_bib9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0014-5793(87)80081-9","article-title":"Ca2+\/calmodulin-dependent phosphorylation of elongation factor 2","volume":"214","author":"Ryazanov","year":"1987","journal-title":"FEBS Lett"},{"key":"2022061702445726300_bib10","first-page":"2260","article-title":"Phosphorylation of elongation factor 2 in normal and malignant rat glial cells","volume":"53","author":"Bagaglio","year":"1993","journal-title":"Cancer Res"},{"key":"2022061702445726300_bib11","first-page":"1403","article-title":"Role of calmodulin-dependent phosphorylation of elongation factor 2 in the proliferation of rat glial cells","volume":"5","author":"Bagaglio","year":"1994","journal-title":"Cell Growth Differ"},{"key":"2022061702445726300_bib12","first-page":"615","article-title":"Calmodulin-dependent protein kinases in rat glioblastoma","volume":"6","author":"Cheng","year":"1995","journal-title":"Cell Growth Differ"},{"key":"2022061702445726300_bib13","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.bjc.6690012","article-title":"Activity and regulation by growth factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer","volume":"79","author":"Parmer","year":"1999","journal-title":"Br J Cancer"},{"key":"2022061702445726300_bib14","first-page":"6894","article-title":"Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines","volume":"63","author":"Arora","year":"2003","journal-title":"Cancer Res"},{"key":"2022061702445726300_bib15","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/0008-5472.CAN-05-1554","article-title":"Elongation factor-2 kinase regulates autophagy in human glioblastoma cells","volume":"66","author":"Wu","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702445726300_bib16","doi-asserted-by":"crossref","first-page":"e9715","DOI":"10.1371\/journal.pone.0009715","article-title":"Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition","volume":"5","author":"Cheng","year":"2010","journal-title":"PLoS One"},{"key":"2022061702445726300_bib17","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1158\/0008-5472.CAN-08-2872","article-title":"Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy","volume":"69","author":"Wu","year":"2009","journal-title":"Cancer Res"},{"key":"2022061702445726300_bib18","doi-asserted-by":"crossref","first-page":"3178","DOI":"10.1016\/j.bmcl.2008.04.074","article-title":"Allosteric inhibitors of Akt1 and Akt2: a naphthyridinone with efficacy in an A2780 tumor xenograft model","volume":"18","author":"Bilodeau","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"key":"2022061702445726300_bib19","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1158\/1535-7163.MCT-09-1012","article-title":"MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo","volume":"9","author":"Hirai","year":"2010","journal-title":"Mol Cancer Ther"},{"key":"2022061702445726300_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/ncb839","article-title":"TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling","volume":"4","author":"Inoki","year":"2002","journal-title":"Nat Cell Biol"},{"key":"2022061702445726300_bib21","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1038\/emboj.2009.242","article-title":"Modulation of intracellular ROS levels by TIGAR controls autophagy","volume":"28","author":"Bensaad","year":"2009","journal-title":"EMBO J"},{"key":"2022061702445726300_bib22","doi-asserted-by":"crossref","first-page":"e9996","DOI":"10.1371\/journal.pone.0009996","article-title":"Simultaneous induction of non-canonical autophagy and apoptosis in cancer cells by ROS-dependent ERK and JNK activation","volume":"5","author":"Wong","year":"2010","journal-title":"PLoS One"},{"key":"2022061702445726300_bib23","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1200\/JCO.2004.01.103","article-title":"Putting the rap on Akt","volume":"22","author":"Thompson","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022061702445726300_bib24","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1158\/1078-0432.CCR-09-1837","article-title":"Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed\/refractory Waldenstrom's macroglobulinemia","volume":"16","author":"Ghobrial","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2022061702445726300_bib25","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.2007.14.3685","article-title":"Enzastaurin, an oral serine\/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer","volume":"26","author":"Oh","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022061702445726300_bib26","article-title":"Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT","author":"Garrett","journal-title":"Invest New Drugs"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/7\/2654\/2665382\/2654.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/7\/2654\/2665382\/2654.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T07:14:07Z","timestamp":1655450047000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/7\/2654\/574383\/eEF-2-Kinase-Dictates-Cross-Talk-between-Autophagy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,31]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2011,3,31]]},"published-print":{"date-parts":[[2011,4,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-2889","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.9751957.10442055","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,31]]}}}